3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Testicular Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Death
1
Colonic Neoplasms
1
Interventions
Cisplatin
141
Radiotherapy
115
Cetuximab
95
Docetaxel
69
Radiotherapy, Intensity-Modulated
55
Carboplatin
47
pembrolizumab
46
Surveys and Questionnaires
46
Paclitaxel
41
Fluorouracil
39
Radiation
29
Blood Specimen Collection
27
Drug Therapy
26
Erlotinib Hydrochloride
23
Nivolumab
21
Surgical Procedures, Operative
17
Standard of Care
16
Magnetic Resonance Spectroscopy
16
Radiosurgery
14
Pemetrexed
14
Gemcitabine
14
Everolimus
13
Celecoxib
13
durvalumab
12
Low-Level Light Therapy
12
Immunohistochemistry
12
Cyclophosphamide
12
Capecitabine
12
Amifostine
12
Chemoradiotherapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Head and Neck Neoplasms
×
erythromycin propionate-N-acetylcysteinate
×
Clear all
NCT02966509
2018-10-31
EPAC
Stanford University
Phase NA
Completed
213 enrolled
20 charts